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Mycophenolate mofetil alleviates persistent proteinuria in IgA
nephropathy.
Background. Mycophenolate mofetil (MMF) is increasingly
used to treat primary glomerulopathies. Its effectiveness in IgA
nephropathy (IgAN) remains unclear.
Methods. Forty IgAN patients with persistent proteinuria
(>1 g/24 hours) despite conventional treatment with blockers
of the renin-angiotensin system were randomized to receive
MMF for 24 weeks (group 1) or continue conventional therapy
(group 2), and followed for 72 weeks. The primary end point
was reduction of proteinuria by 50% or more over entry level.
Results. Sixteen patients (80%) in group 1 versus six patients
(30%) in group 2 reached the primary end point (P = 0.0019).
Time-averaged change in proteinuria showed a significant de-
cline in group 1, while control subjects displayed a modest rise
(P = 0.003). By 72 weeks, the mean proteinuria was 62.0 ±
7.7% (P = 0.003) and 120.5 ± 14.1% (P = 0.351) that of the
corresponding baseline value in group 1 and group 2, respec-
tively. There was concomitant increase in serum albumin and
decrease in serum IgA levels in group 1 but not group 2 pa-
tients. Baseline histologic grades, blood pressure control, and
the rates of change in serum creatinine and creatinine clear-
ance were not different between the two groups. Normalization
in binding of polymeric IgA to cultured mesangial cells and
serum interleukin-6 (IL-6) levels, which sustained to study end,
was observed in group 1 but not group 2 subjects.
Conclusion. In selected patients with IgAN, MMF is effective
in lowering proteinuria and ameliorating some of the putative
pathogenetic abnormalities.
Immunoglobulin A nephropathy (IgAN) is the most
common primary glomerulonephritis worldwide [1]. The
glomerulopathy usually runs an indolent but slowly pro-
gressive course leading to end-stage renal failure in 20%
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to 50% of patients over 30 years. Given its complex
and as yet incompletely understood pathogenetic mech-
anisms, there is to date no curative therapy for patients
with IgAN. Most clinicians employ blockers of the an-
giotensin system, such as angiotensin-converting enzyme
(ACE) inhibitors or, more recently, angiotensin II re-
ceptor blockers (ARBs) for control of hypertension and
proteinuria. However, many patients remain significantly
proteinuric despite treatment with angiotensin blockade.
Although fish oil supplementation was once thought to
be a promising therapeutic agent for patients with pro-
teinuria of over 1 g/24 hours [2], its therapeutic value
was not reproducible in Chinese subjects with IgAN [3].
Moreover, a recent meta-analysis [4] has cast doubt on
the putative benefit of fish oil supplementation in IgAN.
The predominant glomerular deposition of abnormally
glycosylated polymeric IgA and the frequently elevated
circulating IgA levels in primary IgAN [5] suggest a
pathogenetic role for deranged antibody synthesis. My-
cophenolate mofetil (MMF) acts by releasing mycophe-
nolic acid that selectively suppresses the proliferation of
T and B lymphocytes, antibody formation, and the glyco-
sylation of adhesion molecules through inhibition of de
novo guanine nucleotide synthesis [6]. In clinical trials,
MMF proved to be efficacious for the prophylaxis of re-
nal allograft rejection [7] and for the treatment of severe
lupus nephritis [8] with a favorable safety profile. Fur-
thermore, MMF has been anecdotally reported to avert
progression to allograft failure in recurrent IgAN of the
transplanted kidney [9]. Here, we evaluated the efficacy
of MMF in reducing proteinuria in patients in whom sig-
nificant proteinuria persists despite treatment with an-
giotensin blockade.
METHODS
This was a prospective, randomized, controlled trial
performed in two major regional renal centers in Hong
Kong to test the hypothesis that MMF will lead to a signif-
icant and sustained decline in proteinuria in patients with
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IgAN and persistent proteinuria despite adequate treat-
ment with blockers of the angiotensin system, compared
to a control group of patients receiving comparable doses
of angiotensin inhibition without MMF. The study was
approved by an Institutional Review Board and Ethics
Committee of the Hong Kong Hospital Authority, and
all participating patients gave written, informed consent.
Patient selection
Patients of either gender were eligible if they had his-
tologically confirmed IgAN and clinically significant pro-
teinuria of over 1 g/24 hours on three or more consecutive
measurements 4 to 6 weeks apart despite adequate block-
ade of the angiotensin system, which refers to treatment
with an ACE inhibitor, or an ARB if the patient was in-
tolerant to the former, for at least 6 months to achieve
a target blood pressure of <125/85 mm Hg. This level
of proteinuria was chosen as urine protein excretion of
>1.0 g/24 hours has been shown to be strongly associated
with subsequent development of renal failure in IgAN
[10]. Patients with glomerulopathies other than IgAN,
serum creatinine over 300 lmol/L (3.4 mg/dL), systemic
infection or malignancy, and women of child-bearing age
who were pregnant, lactating, or unwilling to practice re-
liable contraception, were excluded.
All patients were instructed by a dietician to have a
sodium-restricted diet of 50 mmol/day, and regularly fol-
lowed by the same dietician who would obtain full dietary
history, reiterate the need to control salt intake, and an-
swer any queries about different types of diets during
every visit. Dietary compliance was checked by evalu-
ating urinary excretion of sodium every 8 weeks during
follow-up. Due to the large variety of the Chinese diet,
sodium excretion rates not exceeding 80 mmol/24 hours
were considered acceptable.
Histologic assessment
The histologic diagnosis of IgAN was based upon the
demonstration of mesangioproliferative changes on light
microscopy and the concomitant presence of predomi-
nant or codominant mesangial deposition of IgA. Histo-
logic grading of all renal biopsy samples were determined
by a central pathologist in accordance with the classifica-
tion published by Haas [11]. Patients with minimal or no
mesangial hypercellularity (Haas subclass 1) or advanced
glomerulosclerosis and tubular atrophy (Haas subclass
5), were excluded. To provide information on prognosis,
the biopsy samples were also graded with respect to the
extent of glomerular sclerosis, tubular loss, interstitial fi-
brosis, and hyaline arteriolosclerosis, in accordance with
the method developed by To et al [12], who showed that
glomerular sclerosis represents the most important prog-
nostic factor in adult patients with primary IgAN and has
a strong predictive value for renal survival.
Study design
Eligible subjects were randomly assigned to receive
MMF (2 g/day if body weight was ≥ 60 kg, or 1.5 g/day
if body weight was <60 kg) in addition to concurrent
medications (group 1), or to continue contemporaneous
medications without addition of MMF (group 2). The
rationale of choosing this dosing regimen stems from
our experience in Chinese renal transplant recipients
in whom complications such as diarrhea and anemia
are more prevalent in those who receive MMF 2 g/day
and have body weight below 60 kg. The dose of either
ACE inhibitor or ARB was titrated to reach the target
blood pressure of <125/85 mm Hg. Blood pressures were
recorded as the mean of three morning measurements
(to the nearest 2 mm Hg). The first line ACE inhibitor
used was lisinopril or enalapril. The first-line ARB used
was losartan. Additional antihypertensive drugs using the
nondihydropyridine calcium channel blocker diltiazem
and other drugs were allowed, at the attending physi-
cian’s discretion, if target blood pressure was not achieved
despite maximum dose of ACE inhibitor or ARB.
None of the patients were given ACE inhibitor/ARB
combination.
Upon study entry, full medical histories and physical
findings were documented. Baseline investigations in-
cluded full blood count, liver and renal biochemistries, 24-
hour urine protein excretion, creatinine clearance rate,
serum IgA level, plasma total, high-density lipoprotein
(HDL), and low-density lipoprotein (LDL) cholesterol,
and plasma triglyceride levels. Patients were followed ini-
tially at 2-week intervals for the first month, then at 4-
week intervals until 48 weeks. Thereafter, the follow-up
interval was 8 weeks until study end. At each clinic visit,
blood pressure, body weight, blood count, renal function,
24-hour urine sodium, protein, and creatinine clearance
were monitored. Serum IgA level and lipid profile was
measured at weeks 24, 48, and 72. To reduce variability,
all assays were performed at a single central laboratory
using standard methods. In addition, circulating IgA was
isolated from all patients at baseline, weeks 24, 48, and 72
for assay of its binding to cultured human mesangial cells.
Serum interleukin-6 (IL-6) concentration was also deter-
mined at these time points. After 24 weeks, MMF was
discontinued in group 1 patients, who were followed for
a further 48 weeks off MMF, while group 2 patients con-
tinued contemporaneous medications. The entire study
duration for both groups of patients was 72 weeks.
Complete remission of proteinuria was defined as
a value for urinary protein excretion that was below
0.3 g/24 hours; partial remission was defined as a de-
cline in urinary protein excretion by 50% or more over
baseline value but the amount of proteinuria was over
0.3 g/24 hours. Treatment failure was defined as persis-
tence of urinary protein excretion that exceeded 50% of
the baseline value.
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Gastrointestinal upset or diarrhea in group 1 patients
was first treated by increasing the dosing interval of MMF
(e.g., from 1 g twice a day to 500 mg four times a day),
followed, if symptoms persisted, by reducing the dose of
MMF by 50% and then gradually increasing it. For pa-
tients who developed anemia (hemoglobin concentration
decreased to less than 10 g/dL), the dose of MMF was
halved and then titrated such that hemoglobin concen-
tration was no less than 10 g/dL.
Study end points
The incidence of remission of proteinuria (complete or
partial) was the primary end point with respect to efficacy
in this study. The rationale for using proteinuria reduction
instead of progression to end-stage renal disease (ESRD)
as the primary outcome measure is twofold. First, there
is now a large body of recent evidence that implicates
the deleterious effect of proteinuria per se on renal func-
tion [13–17], and that lowering proteinuria in patients
with diabetic and nondiabetic glomerular diseases is as-
sociated with long-term preservation of renal function
[18–20]. Second, because of the lengthy time span (typi-
cally over 15 to 20 years) for patients with relatively nor-
mal or slightly impaired renal function at disease onset
to progress to ESRD, it was conceivable that the like-
lihood of detecting significant intergroup differences in
glomerular filtration rate (GFR) within the study period
was remote. Secondary end points included changes in
mesangial binding of serum IgA, serum IL-6 levels, ad-
verse effects (anemia, diarrhea, and infection), doubling
of serum creatinine or ESRD, and changes in peripheral
blood lymphocyte count, creatinine clearance, and serum
IgA levels.
Determination of mesangial binding of serum IgA
Polymeric k-IgA (pIgA) from patients with IgAN had
increased binding to cultured human glomerular mesan-
gial cells [5]. Here, we studied the effect of MMF treat-
ment on this binding property at baseline, weeks 24, 48,
and 72. The binding properties of pIgA isolated from 15
normal healthy control subjects were also determined
for comparison. Primary culture of human glomerular
mesangial cells were obtained from the normal corti-
cal pole of tumor nephrectomy specimens by differential
sieving, as previously described [14]. Serum pIgA was pu-
rified by jacalin affinity chromatography followed by size
exclusion chromatography and quantified by enzyme-
linked immunosorbent assay (ELISA) as previously de-
scribed [21].
Human mesangial cells were grown to log phase. The
cells were adjusted to 5 × 106/mL and 200 lL of cell sus-
pension was used in binding assays. All staining was per-
formed at 4◦C with staining buffer [phosphate-buffered
saline (PBS) with 1% fetal bovine serum (FBS), and
0.1% sodium azide]. The cells were incubated with 100
lL polymeric IgA (50 lg/mL IgA) for 30 minutes. Af-
ter incubation, the cells were washed with staining buffer
and then further incubated with 100 lL of fluorescein
isothiocyanate (FITC)-conjugated F(ab’)2 fragment of
rabbit antihuman IgA. Background control staining was
achieved by reaction with preimmune F(ab’)2 fragment
of fluorescein-labeled isotypic antibody. The stained cells
were analyzed using an analyzer (Coulter Electronic,
Miami, FL, USA). A minimum of 5000 fixed cells for
each sample was analyzed. Binding of pIgA to cells was
evaluated by comparing the mean fluorescence channels.
Results were expressed as mean fluorescence intensity
(MFI).
Assay of serum IL-6 concentration
Serum IL-6 concentration was determined, using a
commercially available ELISA kit from Bender MedSys-
tem (Vienna, Austria) according to manufacturer’s in-
struction, at baseline, weeks 24, 48, and 72. The serum
IL-6 concentration of 15 normal healthy control subjects
was also determined for comparison. The minimal detec-
tion limit of IL-6 was 1.6 pg/mL with intra- and interbatch
precision of 3.2% and 5.2%, respectively.
Statistical analysis
Our crude estimate indicated that the enrollment of
36 patients will achieve 80% power to detect a 50% differ-
ence in the final urine protein excretion between MMF-
treated and control subjects with a significance level (a)
of 0.05 using a two-sided Mann-Whitney test. Assuming
a dropout rate of 10%, the study was designed to enroll
40 patients.
Data are presented as means ± standard error of the
mean (SE). The main efficacy analysis was performed
on an intention-to-treat basis and included patients who
underwent randomization. Continuous characteristics at
the start of treatment were compared with Wilcoxon rank
sum tests. Categorical groups were compared by the chi-
square test and Fisher’s exact test, as appropriate. The
cumulative percentage of patients who achieved remis-
sion of proteinuria was calculated with the Kaplan-Meier
method, and comparisons between groups were made
with the log rank test. Differences between study entry
and study end in each group were tested by Wilcoxon
signed rank test. Change in proteinuria over time be-
tween the two groups was compared using multivariate
analysis of variance (ANOVA) for repeated measures
with adjustment for baseline variations. Linear regression
analysis was used to estimate the annual rates of change in
serum creatinine concentration and creatinine clearance
in each group, and the Mann-Whitney U test was used to
compare intergroup differences. A two-tailed P value of
less than 0.05 was taken as the level of significance.
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477 patients with IgAN screened
76 patients had urine protein
excretion ≥1g/day on 3
consecutive visits
40 patients underwent randomization
20 patients randomly assigned
to receive MMF in addition
to ongoing treatment
20 patients randomly assigned
to continue ongoing treatment
36 patients did not undergo randomization
due to the following reasons:
Serum creatinine ≥3.4 mg/dL (N = 11)
Not received ACEI/ARB for ≥6 months (N = 10)
Histologically of Haas subclass 1 or 5 (N = 6)
Refusal to participate (N = 9)
Fig. 1. Patient recruitment and randomization. Abbreviations are: IgAN, IgA nephropathy; ACEI, angiotensin-converting enzyme inhibitors;
ARB, angiotensin receptor blockers; MMF, mycophenolate mofetil.
RESULTS
Between July 2001 and December 2003, we enrolled
40 Chinese patients into the study, with 20 in each arm.
The design of the study and patient recruitment process
is shown in Figure 1. Baseline demographic and clini-
cal characteristics (Table 1), as well as histologic grading
(Table 2), were similar between the two groups. All group
1 patients completed the 24 weeks of MMF treatment,
and all patients in both groups completed the entire 72-
week study period.
Urine protein excretion
Over the 18-month study period, a total of 22 patients
(16 patients in group 1 vs. 6 patients in group 2) (P =
0.0019) had remission of proteinuria (Fig. 2). In group 1,
four and 12 patients achieved complete (<0.3 g/24 hours)
and partial (≥50% decline over baseline) remissions, re-
spectively. Over 62% (N = 10) of these remissions oc-
curred during the initial 24 weeks of MMF treatment,
while 38% (N = 6) showed progressive decline in pro-
teinuria that reached the predefined end point during
follow-up after cessation of MMF at week 24. Four pa-
tients had treatment failure. In group 2, one and five pa-
tients achieved complete and partial remissions, respec-
tively. Fourteen subjects (70%) had persistent proteinuria
throughout the study period. The percentage change in
urinary protein excretion relative to that at study entry
was shown in Figure 3. Patients who received MMF dis-
played a steady decline in proteinuria during treatment,
which was sustained after MMF withdrawal at week 24.
Control subjects showed a modest rise in proteinuria dur-
ing the study period. By 72 weeks of follow-up, the mean
urinary protein excretion was 62.0 ± 7.7% (P = 0.003)
and 120.5 ± 14.1% (P = 0.351) that of the corresponding
baseline value in group 1 and group 2, respectively. The
mean urine protein loss was significantly lower in group 1
(1.14 ± 0.23 g/24 hours vs. 2.40 ± 0.40 g/24 hours in group
2) (P = 0.009).
The decrease in proteinuria in group 1 patients was
associated with a concomitant, albeit modest, increase in
serum albumin level from 3.83 ± 0.06 g/dL at baseline
to 3.94 ± 0.07 g/dL at the end of MMF treatment (P =
0.025), and 4.0 ± 0.06 g/dL at week 72 (P = 0.003). There
was no significant change in serum albumin in group 2
patients throughout the study period.
Changes in blood counts
Peripheral blood lymphocyte count during the initial
24 weeks dropped progressively in group 1, but not group
2, patients (Fig. 4). The mean percentage change at week
24 was significantly greater in MMF-treated versus con-
trol patients (−22.5 ± 3.9 vs. +0.5 ± 4.5%) (P < 0.001).
Lymphocyte count in group 1 patients rebounded to pre-
treatment levels within 4 weeks of discontinuing MMF.
There was no appreciable change in neutrophil count
throughout the study. Hemoglobin fell by a mean of 0.9 ±
0.25 g/dL at the end of MMF treatment (P = 0.002)
and returned to baseline levels 12 weeks later in group
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Table 1. Baseline clinical characteristics of 40 patients with IgA
nephropathy (IgAN)a
Group 1 Group 2
Characteristic (N = 20) (N = 20)
Age years 42.1 ± 2.6 43.3 ± 2.8
Gender male:female 6:14 8:12
Time from biopsy to
randomization months
22 ± 13.7 29 ± 10.9
Number of antihypertensive drugs 1.4 ± 0.2 1.7 ± 0.2
On angiotensin-converting
enzyme inhibitors:on
angiotensin receptor blocker
16:4 14:6
Lisinopril (dose in mg/day) 10 (16 ± 3.9) 9 (14.2 ± 5.0)
Enalapril (dose in mg/day) 6 (14.2 ± 4.9) 5 (13 ± 6.7)
Losartan (dose in mg/day) 4 (87.5 ± 25) 6 (83.3 ± 25.8)
Diltiazem (dose in mg/day) 6 (95 ± 44.2) 8 (127.5 ± 57.3)
Atenolol (dose in mg/day) 2 (50 each) 3 (75 ± 25)
Body weight kg 63.8 ± 3.2 64.2 ± 3.7
Blood pressure mm Hg
Systolic 120 ± 3.2 122 ± 3.2
Diastolic 74 ± 2.2 71 ± 2.6
Hemoglobin g/dL 12.8 ± 0.3 12.7 ± 0.4
Lymphocyte count ×109/L 2.2 ± 0.11 1.9 ± 0.12
Serum creatinine mg/dLb 1.53 ± 0.17 1.65 ± 0.23
Creatinine clearance mL/min/1.73
m2 body surface area
75 ± 7.3 69 ± 7.1
Serum albumin g/dLc 3.83 ± 0.06 3.8 ± 0.08
Urine protein excretion g/24 hours 1.8 ± 0.21 1.87 ± 0.28
Plasma lipid profile mg/dLd
Total cholesterol 218 ± 7.3 203 ± 10.4
High-density lipoprotein
cholesterol
55 ± 2.7 46 ± 3.1
Low-density lipoprotein
cholesterol
132 ± 8.8 123 ± 11.0
Triglycerides 147 ± 19.3 163 ± 33.9
Serum IgA level mg/dL 3.6 ± 0.30 3.2 ± 0.16
aPlus-minus values are means ± SE. P > 0.05 for all comparisons between the
two groups.
bThe normal range for serum creatinine is 0.93 to 1.43 mg/dL. To convert
values to micromol/L, multiply by 88.4.
cThe normal range for serum albumin is 4.2 to 5.4 g/dL.
dTo convert values for cholesterol to mmol/L, multiply by 0.02586; to convert
values for triglycerides to mmol/L, multiply by 0.01129.
1 patients, but was unchanged in group 2 patients (data
not shown).
Changes in serum IgA and biochemistries
The mean serum IgA concentration decreased from
360 ± 30 mg/dL at baseline to 320 ± 30 mg/dL at the end
of MMF treatment (P = 0.001), and 330 ± 33 mg/dL at
weeks 48 and 72 (P = 0.003 for both time points) in group
1 patients, but was unchanged in group 2 patients.
Though three patients (15%) in the control group ver-
sus one patient (5%) in the MMF group experienced a
50% or more increase in serum creatinine levels, there
was no difference in the overall rates of change in serum
creatinine and creatinine clearance between the two
groups over the study period (Fig. 5). The median change
in serum creatinine was −0.013 mg/dL/year in the MMF
group and +0.108 mg/dL/year in the control group (P =
NS). There was no appreciable change in plasma lipids in
both groups (data not shown).
Table 2. Baseline histologic characteristicsa
Group 1 Group 2
Characteristic (N = 20) (N = 20)
Number of glomeruli sampled 19.2 ± 6.9 21.8 ± 8.2
Morphologic score distributionb
Grade II 5 7
Grade III 11 11
Grade IV 4 2
Presence of crescents 0 0
Prognostic score distributionc
Glomerular grading (GG)
GG 1 14 15
GG 2 6 5
GG 3 0 0
Tubulointerstitial grading (TIG)
TIG 1 13 11
TIG 2 7 9
TIG 3 0 0
Hyaline arteriolosclerosis (HA)
Absent 16 15
Present 4 5
aPlus-minus values are means ±SE. P > 0.05 for all comparisons between the
two groups.
bDetermined in accordance with the classification by Haas [11], taking into
account the degree of mesangial proliferation, glomerular sclerosis, and tubular
atrophy, on a scale of 1 to 5. Grade 1 indicates minimal histologic changes, while
grade 5 indicates advanced sclerosis and cortical tubular loss.
cDetermined in accordance with the grading by To et al [12]. GG 1, mean
sclerosis per glomerulus, 0% to <25%; GG 2, 25% to <50%; and GG 3, ≥50%.
TIG 1, tubular atrophy and interstitial fibrosis were absent or in an area <5%;
TIG 2, 5% to <50%; and TIG 3, ≥50%. HA was defined as the presence of
arteriolar hyaline or proteinaceous exudation, with or without smooth muscle
hyperplasia or luminal reduction.
Blood pressure changes and urinary sodium excretion
All subjects achieved target systolic and diastolic blood
pressures upon study entry (Table 1). The number of
subjects receiving an ACE inhibitor vs. ARB was 16:4
in group 1, and 14:6 in group 2. Six subjects in group 1
and eight subjects in group 2 required additional antihy-
pertensive agents: four required one additional drug and
two required two additional drugs in group 1, while the
corresponding numbers for group 2 are five and three,
respectively. Throughout the study the average systolic
blood pressure was 122 ± 4 mm Hg and the average di-
astolic blood pressure was 71 ± 2 mm Hg in group 1; the
corresponding values in group 2 were 127 ± 4 mm Hg and
72 ± 3 mm Hg, respectively (P = NS for comparisons of
systolic and diastolic blood pressures between groups).
Blood pressure levels did not change significantly in both
groups throughout the entire study duration (Fig. 6).
All patients complied with dietary sodium restriction
and urine sodium excretion rates achieved the target of
being less than 80 mmol/24 hours throughout the study
period (Fig. 7).
Mesangial binding of pIgA and serum IL-6 concentration
Mesangial binding of pIgA and serum IL-6 concen-
tration was determined in group 1 and group 2 patients,
as well as in 15 normal healthy volunteer subjects. The
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mesangial binding of pIgA isolated from both group 1
and group 2 patients at baseline was significantly higher
than that from healthy controls. In MMF-treated IgAN
patients, the binding was reduced to levels comparable
to those of healthy control subjects after 24 weeks of
treatment, and remained at this low level for a further
48 weeks after MMF was withdrawn. Mesangial binding
in control IgAN patients showed an initial decrease, but
remained significantly higher than that of MMF-treated
patients and healthy control subjects at 24 weeks and be-
yond (Fig. 8A).
Serum IL-6 concentration in both groups of patients
was significantly higher at baseline than that of healthy
controls. At weeks 48 and 72, serum IL-6 concentration
dropped to levels comparable to those of healthy subjects
in group 1, but remained unchanged in group 2 (Fig. 8B).
Side effects
MMF was well tolerated. None of the patients re-
quired drug discontinuation or had any adverse event that
warranted hospitalization. All patients completed the
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24-week course of MMF. Twelve subjects with body
weight over 60 kg were prescribed 2 g/day, while the re-
maining were given 1.5 g/day. Three patients developed a
fall in hemoglobin level to below 10 g/dL that improved
after dose adjustment during the first 4 weeks (2 from 1.5
g/day to 1 g/day, and 1 from 2 g/day to 1.5 g/day). One of
the anemic patients also developed diarrhea, and another
patient experienced transient upper gastrointestinal up-
set. There were a total of three infective episodes (two of
urinary tract infection, and one of cervical lymphadenitis)
in two group 1 patients, and all responded to simple oral
antibiotic treatment. No adverse event was documented
in group 2 patients.
DISCUSSION
In addition to its established benefits in solid organ
transplantation, emerging data in recent years show that
MMF may hold promise for the treatment of a vari-
ety of primary glomerulopathies [22, 23]. The rationale
for employing MMF to treat IgAN, a disorder believed
to be immune-mediated and result from aberrant syn-
thesis of the IgA molecule [24] stems from its selec-
tive suppressive effects on lymphocyte proliferation and
antibody formation [6]. In a recent trial, Maes et al
[25] reported from Belgium no benefit in 21 patients
who received MMF versus 13 patients given placebo for
3 years. Only patients with histologic unfavorable criteria,
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Fig. 7. Fluctuations in urine sodium excretion rates throughout the
study period. MMF is mycophenolate mofetil.
arterial hypertension, and inulin clearance between 21
and 69 mL/min were included in their study, while those
with mild histopathologic changes but heavy proteinuria
were excluded. In addition, Frisch et al [abstract; Frisch
G, et al, J Am Soc Nephrol 14:753A, 2003] reported no
benefit of MMF given for 1 year as a “salvage” therapy
in 16 patients with advanced renal insufficiency, while ac-
knowledging the possibility of insufficient power in their
trial. On the other hand, Chen et al [26] reported in the
Chinese literature that MMF given for 12 months was
more effective than corticosteroid therapy in reducing
proteinuria in IgAN subjects with urinary protein excre-
tion over 2 g/24 hours. However, it was not stated whether
these subjects had been treated with ACE inhibitor/ARB
or fish oil prior to and during the study. Thus, based on
current knowledge, it remains unclear whether MMF is
useful in the subset of patients with less severe disease,
in whom immunosuppressive treatment could have had
a therapeutic impact.
Here, we showed that the addition of MMF led to
significant and sustained lowering of proteinuria in pa-
tients with IgAN and persistent proteinuria of more than
1 g/24 hours despite adequate angiotensin II suppression.
These beneficial effects, as opposed to the negative results
reported by other groups [25] [abstract; Frisch G, et al,
J Am Soc Nephrol 14:753A, 2003] likely result from our
selection of patients with less advanced disease, as re-
flected by their histologic grades. Unfavorable prognostic
indicators in IgAN include proteinuria >3g/day, hema-
turia, male gender, age, and crescents in renal histology
[27]. Current clinical and experimental evidence [28–30]
support the view that antiproteinuric and immunosup-
pressive treatment should be administered at an early
phase of disease, well before histologic damage becomes
irreversible, in order to achieve renal protection. Al-
though most of the MMF-treated patients achieved only
partial remission of proteinuria in our relatively short-
term study, its long-term impact on renal survival could
be potentially far-reaching as proteinuria reduction has
been independently shown by various investigators to
correlate with preservation of renal function [18–20]. Re-
cent post hoc analyses from the RENAAL [31] and REIN
[32] trials, for instance, have confirmed that reduction of
albuminuria during the first 6 months of antiproteinuric
treatment was associated with a reduced rate of GFR
decline and risk of developing renal end point (ESRD)
during long-term follow-up in diabetic and nondiabetic
subjects, respectively. Reduction of proteinuria by ≥30%
at 6 months was a favorable determinant of renal outcome
(with significantly reduced hazard ratios for doubling of
serum creatinine and ESRD) at 4 years [31]. The poten-
tial significance of partial remission of proteinuria is fur-
ther supported by observations in other forms of primary
nephropathy. Troyanov et al [33] recently reported partial
remission as an important therapeutic target and prog-
nostic indicator in idiopathic membranous nephropathy.
Indeed, proteinuria itself should now be considered
a chief therapeutic target in glomerulopathies. In ad-
dition to clinical evidence, we and others have shown
that abnormal protein trafficking may cause renal injury
dose-dependently through the induction in renal tubular
cells of a variety of proinflammatory and profibrotic cy-
tokines, notably complement C3, monocyte chemoattrac-
tant protein-1 (MCP-1), IL-8, fibronectin, macrophage
migration inhibitory factor [13–17], and more recently
transforming growth factor-b (TGF-b) and its surface re-
ceptor [34, 35]. These cytokines in turn stimulate intersti-
tial leukocyte infiltration, inflammation, and ultimately,
scarring and loss of renal function. Thus, it is conceiv-
able that excessive intrarenal protein trafficking may give
rise to lymphocyte-mediated renal injury that, when un-
controlled by conventional antiproteinuric therapy, can
be further inhibited by concomitant immunosuppression
with MMF.
Although there was no demonstrable difference in the
rates of change in serum creatinine and creatinine clear-
ance over the study period between the two groups, this
is not unexpected as renal failure in IgAN typically takes
15 to 30 years to develop from disease onset [36]. As such,
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Fig. 8. Binding to cultured mesangial cells
by polymeric IgA (pIgA) isolated from pa-
tients and healthy subjects (A), and serum
interleukin-6 (IL-6) concentration in patients
and healthy subjects (B). (A) Polymeric IgA
was isolated from IgA nephropathy (IgAN)
patients at baseline, weeks 24, 48, and 72,
and its binding to cultured glomerular mesan-
gial cells was determined by flow cytometry
and expressed as mean fluorescent intensity
(MFI). The binding of pIgA isolated from
15 healthy volunteer subjects was also deter-
mined for comparison. ∗P < 0.001; †P = 0.028;
‡P = 0.016 vs. healthy subjects; §P = 0.002 vs.
baseline; #P = 0.05; ¶P = 0.004; ‖P = 0.047 vs.
corresponding time points in group 2 (control
IgAN subjects). Error bars are means ± SE.
(B) Serum IL-6 concentration was assayed
at baseline, weeks 24, 48, and 72. The mean
serum IL-6 level (3.61 ± 0.5 pg/mL) of the
15 healthy volunteer subjects was also deter-
mined for comparison. ∗P < 0.001; †P = 0.005;
‡P = 0.041; ∗∗P = 0.048 vs. healthy subjects;
§P =0.001;¶P =0.003 vs. baseline; #P =0.005;
‖P = 0.008 vs. corresponding time points in
group 2 (control IgAN subjects). ∗P < 0.001;
†P = 0.005; ‡P = 0.04 vs. healthy subjects. Er-
ror bars are means ± SE.
it will be difficult for any short-term study, including the
present study, to detect significant differences in GFRs.
Indeed, another randomized controlled trial of MMF in
IgAN is currently under way in North America [37]. Sim-
ilar to our report, the trial is also designed to explore
the clinical efficacy of MMF, to be given for 12 months
followed by a year of follow-up off study drug, in reduc-
ing proteinuria in IgAN subjects with significant protein-
uria despite treatment with an ACE inhibitor and fish
oil supplementation for 3 months. The primary end point
will be change in urine protein-to-creatinine ratio. We
are not aware of any ongoing trial of MMF that employs
renal survival in terms of either doubling of serum crea-
tinine or progression to ESRD as the primary outcome
measure.
In addition to proteinuria, lymphocyte count and
serum IgA levels were also suppressed during MMF treat-
ment. Interestingly, while lymphocyte count predictably
returned to pretreatment levels after MMF was discon-
tinued, serum IgA remained lower, albeit to a modest
degree, than pretreatment levels at 48 and 72 weeks. The
sustained lowering of serum IgA may be related to the
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fact that MMF selectively inhibits proliferation of ac-
tivated lymphocytes, which become inactivated, and is
consistent with the capacity of MMF to block antibody
formation by activated B lymphocytes in both human and
murine systems [38]. Recent data from our laboratory and
others suggest a structural aberration of the IgA molecule
in IgAN that may exert pathophysiologic effects on tar-
get cells [39–41], reduce clearance of IgA-immune com-
plexes [41, 42], or favor mesangial trapping of immune
complexes [5, 21]. Thus, it is possible that even small re-
ductions in IgA production by B lymphocytes as a result
of purine nucleotide depletion through MMF adminis-
tration could lead to overall attenuation of glomerular
injury in IgAN. The validity of such contention requires
further studies.
From a mechanistic viewpoint, we have previously
demonstrated in vitro that the pIgA subfraction from pa-
tients with IgAN had increased binding to cultured hu-
man glomerular mesangial cells [5]. The aberrant binding
properties of these antibodies could explain the charac-
teristic observation of predominant mesangial IgA de-
posits in IgAN, and may provide one of the pathogenetic
mechanisms for the disease. The high levels of binding ob-
served in our patients at baseline are consistent with this
finding. MMF profoundly attenuated mesangial binding
of pIgA isolated from IgAN subjects to levels comparable
to those from normal subjects. This low level of binding
persisted after MMF was withdrawn. Besides mesangial
cell binding, participation of the cytokine IL-6 is also im-
plicated in the pathogenesis of IgAN through its role in
stimulating mesangial cell proliferation and synthesis of
extracellular matrix macromolecules [1, 43, 44], which are
additional hallmarks of IgAN. Recent data suggest that
an imbalance in serum proinflammatory cytokines, such
as overproduction of IL-6, is linked to disease progres-
sion in IgAN [45]. Our finding of elevated serum IL-6
concentration compared with normal controls is consis-
tent with the previous report of heightened IL-6 gene
expression in peripheral blood T cells of IgAN subjects
with proteinuria >1 g/24 hours [46]. Furthermore, a pos-
itive correlation was noted between serum IL-6 mRNA
level and the quantity of proteinuria [46]. Thus, it is pos-
sible that one of the proteinuria-lowering mechanisms of
MMF is mediated through suppression of IL-6 synthesis,
which is consistent with its effects in suppressing other
cytokines [38]. The pathogenetic role of IL-6 in IgAN
is further supported by observations that suppression of
IL-6 by mizoribine, a mold extract that also selectively in-
hibits lymphocyte proliferation, improves glomerular le-
sions in childhood IgAN and in ddY mice, a rodent model
of IgAN [47–49]. In addition, MMF has been shown in
animal models of subtotal renal ablation to possess di-
rect anti-inflammatory and antiproliferative effects that
attenuate macrophage and T-cell infiltration [50], and re-
duce interstitial myofibroblast infiltration and collagen
deposition [51]. Furthermore, direct inhibition of mesan-
gial proliferation may be another effect of the drug, as
in vitro proliferation of human and rat mesangial cells is
inhibited by MMF in a dose-dependent manner [52]. The
diverse mechanisms of action of MMF are also reflected
by its efficacy in glomerulopathies other than IgAN [23].
Whether the improvements in all these clinical and ex-
perimental parameters from MMF treatment may trans-
late into a tangible advantage in overall renal outcome in
IgAN requires long-term observation. Our results point
to the fact that careful selection of the candidate who may
benefit from MMF treatment is of fundamental impor-
tance. Patients with advanced disease may not warrant
immunosuppression at all, while patients with low-grade
proteinuria or those who respond to angiotensin inhibi-
tion should not be subjected to the risks of undue im-
munosuppression. The duration of treatment should be a
delicate balance weighed between the potential risks and
benefits of immunosuppressive therapy. Further investi-
gation is needed to dissect the exact mechanisms respon-
sible for the observed biologic effects of MMF in IgAN.
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